检验医学 ›› 2016, Vol. 31 ›› Issue (11): 936-940.DOI: 10.3969/j.issn.1673-8640.2016.011.002

• 临床应用研究·论著 • 上一篇    下一篇

羟苯磺酸钙对酶法游离脂肪酸检测的负干扰

侯立安1, 国秀芝1, 邱玲1, 程歆琦1, 张波2, 禹松林1, 方慧玲1, 赵芳1, 刘茜1   

  1. 1.中国医学科学院北京协和医院检验科,北京 100730
    2.中国医学科学院北京协和医院药剂科,北京 100730
  • 收稿日期:2016-01-04 出版日期:2016-11-30 发布日期:2016-12-22
  • 作者简介:null

    作者简介:侯立安,女,1989年生,学士,技师,主要从事临床生化检验工作。

    通讯作者:邱 玲,联系电话:010-69159707。

  • 基金资助:
    首都卫生发展科研专题项目(首发2016-2-4017)

Negative interference by calcium dobesilate in enzymatic assays of free fatty acid

HOU Li'an1, GUO Xiuzhi1, QIU Ling1, CHENG Xinqi1, ZHANG Bo2, YU Songlin1, FANG Huiling1, ZHAO Fang1, LIU Qian1   

  1. 1. Department of Clinical Laboratory,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences,Beijing 100730,China
    2. Department of Pharmacy,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences,Beijing 100730,China
  • Received:2016-01-04 Online:2016-11-30 Published:2016-12-22

摘要:

目的 探讨羟苯磺酸钙对6种酰基辅酶A合成酶(ACS)-过氧化物酶偶联法(简称ACS酶法)检测游离脂肪酸(FFA)的干扰及对临床的影响。方法 用去离子水配制不同浓度羟苯磺酸钙溶液,添加到2种不同FFA浓度(550和1 200 μmol/L)基础血清中,药物终浓度分别为0、2、4、8、16、32、64 μg/mL。用6种ACS酶法试剂盒(以A、B、C、D、E、F随机顺序编号)测定添加了药物溶液的血清FFA浓度,计算与药物浓度为0 μg/mL时的百分偏差,以±5%作为干扰可接受范围。采用高效液相色谱法(HPLC)监测志愿者服药前、后血清中羟苯磺酸钙浓度变化与时间[服药前及0(即药物浓度达稳态后的谷浓度)、1、2、3、4、6 h]的关系,并测定40例临床服用羟苯磺酸钙患者的血清药物浓度。结果 羟苯磺酸钙药物稳态谷浓度(0 h)[中位数(四分位数间距)]为6.64(5.64~7.86)μg/mL;服药500 mg后,药物浓度在2~3 h达峰值,峰浓度为15.00(13.63~19.67)μg/mL,随后逐渐下降。40例服药患者血清中羟苯磺酸钙的平均浓度为11.92(5.45~19.22) μg/mL。在体外实验中,随着血清中羟苯磺酸钙浓度的增加,FFA检测结果的受干扰程度亦相应增强。当血清中羟苯磺酸钙浓度为8 μg/mL时,6种试剂盒检测低浓度(550 μmol/L)、高浓度(1 200 μmol/L)FFA的偏差为-0.40%~-65.01%和-0.20%~-52.33%,除B、D 2种试剂盒外,其他4种试剂盒的干扰程度均在可接受范围内。当血清中的羟苯磺酸钙浓度为16 μg/mL时,6种试剂盒检测低、高浓度FFA的偏差分别为-1.68%~-28.28%和-1.81%~-16.48%,除A试剂盒和C试剂盒(高浓度FFA)外,其他试剂盒及C试剂盒(低浓度FFA)的检测结果均明显超出了干扰可接受范围。干扰程度也与基础血清的FFA浓度有关,在同一药物浓度下,FFA浓度越低,干扰越明显。结论 羟苯磺酸钙对ACS酶法检测FFA会产生不同程度的负干扰,应引起重视。

关键词: 游离脂肪酸, 羟苯磺酸钙, 酶法, 干扰

Abstract:

Objective To investigate the interference of calcium dobesilate in the determination of free fatty acid(FFA) using 6 acetyl-coenzyme A synthetase (ACS)-peroxidase coupled assays and its influence. Methods Calcium dobesilate solution with different concentrations was prepared by pure water,and was added into sera with 2 different FFA concentrations(550 and 1 200 μmol/L). Serum FFA levels with final concentrations of calcium dobesilate additions(0,2,4,8,16,32 and 64 μg/mL) were determined using 6 ACS enzymatic assays(A,B,C,D,E and F,randomly). Bias(%) was calculated in serum FFA with final concentration of calcium dobesilate addition(0 μg/mL). Taking ±5% as an acceptable range of interference,the changes in serum calcium dobesilate levels observed before and after calcium dobesilate administration [baseline,0 h(valley concentration of drug in the stable state),1 h,2 h,3 h,4 h and 6 h] in 40 participants were monitored by high performance liquid chromatography(HPLC). Serum calcium dobesilate levels in 40 participants from those taking calcium dobesilate were determined. Results The level of serum calcium dobesilate(0 h) [median(interquartile range)] was 6.64(5.64-7.86)μg/mL. After taking 500 mg,the level of serum calcium dobesilate peaked at 2-3 h. The peak level of serum calcium dobesilate was 15.00(13.63-19.67)μg/mL,and then decreased gradually. The average level in 40 participants was 11.92(5.45-19.22)μg/mL. With the increase of serum calcium dobesilate level,the degree of interference in FFA determination also increased in in vitro experiment. For the low and high concentrations(550 and 1 200 μmol/L) of serum FFA,the biases in 6 ACS enzymatic assays were -0.40% - -65.01% and-0.20% - -52.33% in 8 μg/mL serum calcium dobesilate. The interference degrees of 4 ACS enzymatic assays can be accepted,except B and D. The biases in 6 ACS enzymatic assays were -1.68% - -28.28% and -1.81% - -16.48% in 16 μg/mL serum calcium dobesilate. Except kit A and kit C(high concentration of FFA),the interference of other kits and kit C(low concentration of FFA) was beyond the acceptable range. The degree of interference was also related with basic serum FFA concentration. Under same calcium dobesilate concentration,the interference with lower concentration of serum FFA was more obvious. Conclusions In ACS enzymatic assays,calcium dobesilate produces a negative interference in the determination of FFA.

Key words: Free fatty acid, Calcium dobesilate, Enzymatic assays, Interference

中图分类号: